TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - ASTRAZENECA TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - ASTRAZENECA Stock
Certificat
DE000SQ0WR97
| Delayed Deutsche Boerse AG 08:28:27 2024-05-21 am EDT | ||
| 0.59 EUR | -9.23% |
|
| Current month | -12.16% | ||
| 1 month | -65.24% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 24-05-21 | 0.59 | -9.23% |
| 24-05-20 | 0.65 | +3.17% |
| 24-05-17 | 0.63 | +6.78% |
| 24-05-16 | 0.59 | +3.51% |
| 24-05-15 | 0.57 | +50.00% |
Delayed Quote Deutsche Boerse AG
Last update May 21, 2024 at 08:28 am EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | SQ0WR9 |
| ISIN | DE000SQ0WR97 |
| Date issued | 2022-09-23 |
| Strike | 12,612 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.54 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.06 € |
|---|---|
| Lowest since issue | 0.32 € |
| Spread | 0.01 € |
| Spread % | 1.67% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
153.7
USD
Average target price
168.1
USD
Spread / Average Target
+9.41%
- Stock Market
- Certificates
- Certificat